Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$4.75 USD
+0.55 (12.98%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.74 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Ocular Therapeutix, Inc. [OCUL]
Reports for Purchase
Showing records 1 - 20 ( 85 total )
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
2023 Financial Results Reported; Reiterate Buy; Raising PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Phase 3 Wet AMD Trial Starts Patient Screening; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Wet AMD Pivotal Trial SPA Amended to Accelerate Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Special Protocol Assessment Obtained For the Wet AMD Pivotal Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
First Pivotal Trial in Wet AMD Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Top- and Bottom-Line Beat in 2Q23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Positive 12-Month Data in Wet AMD; Reiterate Buy; Raising PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Phase 1 Diabetic Retinopathy Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
1Q23 Financial Results Reported; Reiterate Buy; Adjusting PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Full-Year 2022 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Positive 10-Month Data Reported in Wet AMD; Reiterate Buy; Raising PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Preliminary 2022 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
3Q22 Financial Results Reported; Reiterate Buy; Modulating PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Interim 7-Month Wet AMD Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Positive Interim 7-Month Data Reported in Wet AMD; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
1Q22 Financial Results Reported; Reiterate Buy; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y